ERG and prostate carcinoma: It is well known that about the half of prostate cancers carry a gene fusion, which links the androgen-regulated serine protease TMPRSS2 with the ETS-transcription factor ERG resulting in an androgen-related expression of ERG with subsequent dysregulation of more than 1600 ERG target genes [17–19].